A RANDOMIZED CONTROLLED PHASE 3 TRIAL OF RESMETIROM IN NONALCOHOLIC STEATOHEPATITIS: 52-WEEK DATA FROM MAESTRO-NASH

Jörn Schattenberg  ¹     Pierre Bedossa  ²     Cynthia D. Guy  ³     Rohit Loomba  ⁴     Rebecca Taub  ⁵     Dominic Labriola  ⁵     Sam E. Moussa  ⁶     Guy W. Neff  ⁷     Arun J Sanyal  ⁸     Mazen Noureddin  ⁹     Meena Bansal  ¹⁰     Naim Alkhouri  ¹¹     Vlad Ratziu  ¹²     Stephen A. Harrison  ^13    
1 Universitätsmedizin Mainz, Mainz, Germany
² Université Paris-Diderot Hopital Beaujon, Paria, France
³ Duke University Medical Center, Durham, United States
⁴ University of California San Diego, San Diego, United States
⁵ Madrigal Pharmaceuticals, Conshohocken, United States
⁶ University of Arizona for Medical Sciences, Tucson, United States
⁷ Covenant Metabolic Specialists, Sarasota, United States
⁸ Virginia Commonwealth University School of Medicine, Richmond, United States
⁹ Cedars-Sinai Medical Center, Los Angeles, United States
¹⁰ Mt Sinai, New York, United States
¹¹ Arizona Liver Health, Tucson, United States
¹² Hôpital Pitié Salpêtrière, Paris, France
¹³ Pinnacle Clinical Research, San Antonio, United States

Topic
Hepatobiliary

Session
Opening Plenary

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)